Planning for human papillomavirus vaccines in Australia: Report of a research group meeting
DOI:
https://doi.org/10.33321/cdi.2004.28.25Keywords:
HPV vaccine, sexually transmissible infections, human papilloma virusAbstract
This report discusses human papillomavirus (HPV) which is the most common viral sexually transmitted infection, with estimates that up to 75 per cent of people are infected at some time. Whilst most infection resolves without symptoms, some human papillomavirus infections can persist and cause cancer.
Downloads
References
Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997;102:3-8.
Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HHPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991;185:251-257.
Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645-16451.
Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003;88:63-73.
Ferlay J, Bray F, Pisani P and Parkin DM. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0. International Agency for Research on Cancer CancerBase No. 5. Lyon, IARC Press, 2001.
Australian Institute of Health and Welfare. Cervical screening in Australia 2000-2001 and 1999-2000. (Cancer series number 24). Australian Institute of Health and Welfare Cat No.19. Canberra: 2003
Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19.
Chen S, O'Sullivan HO, Tabrizi SN, Fairley CK, Quinn MA, Garland SM. Prevalence and genotyping of HPV in cervical cancer among Australian women. Int J Gynaecol Obstet 1999;67:163-168.
Thompson CH, Rose BR, Elliott PM. Cytomegalovirus and cervical cancer: failure to detect a direct association or an interaction with human papillomaviruses. Gynecol Oncol 1994;54:40-46.
Liu JH, Huang X, Liao GW, Li JD, Li YF, Li MD, et al. Human papillomavirus infection and other risk factors for cervical cancer in Chinese and Australian patients. Natl Med J China 2003;83:748-752.
Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003;290:781-789.
Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 2000;151:1158-1171.
Hughes JP, Garnett GP, Koutsky L. The theoretical population-level impact of a prophylactic human papilloma virus vaccine. Epidemiology 2002;13:631-639.
Bowden FJ, Paterson BA, Mein J, Savage J, Fairley CK, Garland SM, et al. Estimating the prevalence of Trichomonas vaginalis, Chlamydia trachomatis, and Neisseria gonorrhoeae, and human papillomavirus infection in indigenous women in northern Australia. Sex Transm Infect 1999;75:431-434.
Fairley CK, Chen S, Tabrizi SN, Walker R, Atkins RC, Garland SM. Prospective study of HPV DNA in cervical specimens from women with renal transplants. Nephrol Dial Transplant 1994;9:1520-1523
Fairley CK, Chen S, Tabrizi SN, Leeton K, Quinn MA, Garland SM. The absence of genital human papillomavirus DNA in virginal women. Int J STD AIDS 1992;3:414-417.
Tabrizi SN, Fairley CK, Chen S, Borg AJ, Baghurst P, Quinn MA, et al. Epidemiological characteristics of women with high grade CIN who do and do not have human papillomavirus. Br J Obstet Gynaecol 1999;106:252-257.
Richardson H, Kelsall G, Tellier P, Voyer H, Abrahamowicz M, Ferenczy A, et al. The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev 2003;12:485-490.
Schlecht NF, Platt RW, Duarte-Franco E, Costa MC, Sobrinho JP, Prado JC, et al. Human Papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst 2003; 95: 1336-1343.
Zhang WH, Coppleson M, Rose BR, Sorich EA, Nightingale BN, Thompson CH, et al. Papillomavirus and cervical cancer: a clinical and laboratory study. J Med Virol 1988;26:163-174.
Thompson CH, Rose BR, Cossart YE. Detection of HPV DNA in archival specimens of cervical cancer using in situ hybridisation and the polymerase chain reaction. J Med Virol 1992;36:54-59.
Parker BJ, Cossart YE, Thompson CH, Rose BR, Henderson BR. The clinical management and laboratory assessment of anal warts. Med J Aust 1987;147:59-63.
Law CL, Merianos A, Grace J, Rose BR, Thompson CH, Cossart YE. Clinical and virological associations between external anogenital warts and cervical HPV infection in an STD clinic population. Int J STD AIDS 1991;2:30-36.
Watts KJ, Thompson CH, Cossart YE, Rose BR. Variable oncogene promoter activity of human papillomavirus type 16 cervical cancer isolates from Australia. J Clin Microbiol 2001;39:2009-2014.
Li W, Thompson CH, O'Brien CJ, McNeil EB, Scolyer RA, Cossart YE, et al. Human papillomavirus positivity predicts favourable outcome for squamous carcinoma of the tonsil. Int J Cancer 2003;106:553-558.
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2004 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
